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ABSTRACT: We report on a chemical platform to generate site-speciﬁc, homogeneous, antibody−antibody conjugates by
targeting and bridging disulﬁde bonds. A bispeciﬁc antibody construct was produced in good yield through simple reduction and
bridging of antibody fragment disulﬁde bonds, using a readily synthesized bis-dibromomaleimide cross-linker. Binding activity of
antibodies was maintained, and in vitro binding of target antigens was observed. This technology is demonstrated through linking
scFv and Fab antibody fragments, showing its potential for the construction of a diverse range of bispeciﬁcs.
The limited ability of conventional monoclonal antibodytherapies to induce signiﬁcant antitumor activity has led to
the development of bispeciﬁcs: antibodies that can simulta-
neously bind two diﬀerent antigens. In 2009, catumaxomab
became the ﬁrst bispeciﬁc therapeutic to be clinically approved,
combining EpCAM targeting with T-cell recruitment for the
treatment of malignant ascites.1 Recombinant technologies have
produced a diverse range of bispeciﬁc antibodies, generating
45 formats in the past two decades.2 Despite this variety of topo-
logies, the approach is not suited to every protein combination.
The fusion of proteins via their N or C termini can result in a
reduction or loss of bioactivity and variable expression yields can
be observed due to complications in folding and processing.3−5
An alternative and potentially more versatile approach to
generating bispeciﬁc therapeutics is chemical conjugation. Until
now, this has been a less successful method of producing such
conjugates. A fundamental ﬂaw in the chemical techniques
employed in this area has been their dependence on modifying
lysine residues. There is an average of 100 lysine residues per
antibody, and their distribution is uniform throughout the
surface topology of the Fab and Fc regions. As such, conjugation
techniques using lysine residues will randomly cross-link to
virtually all areas of the antibody molecule, resulting in a highly
heterogeneous mixture of products with unpredictable proper-
ties. One strategy to overcome this issue is provided by site-
directed mutagenesis, which enables a single nucleophilic
cysteine residue to be introduced at a desired site in an antibody.
However, this approach is limited, as cysteine mutagenesis
commonly leads to reduced expression yields and undesirable
properties such as susceptibility to dimerization, mixed disulﬁde
formation, or disulﬁde scrambling.6−8
Recently the site-speciﬁc introduction of chemical linkers
has been reported through unnatural amino acid insertion.9,10
Using this approach, Schultz et al. described the synthesis of a
homogeneous anti-HER2/anti-CD3 bispeciﬁc in good yield.10
This technology, while elegant, is not readily transferred; each
antibody to be conjugated must undergo prior investigation
to determine appropriate mutation sites, substitution for the
unnatural amino acid is often incomplete, and expression yields
are generally low due to the cellular toxicity of artiﬁcial amino
acids at the high concentrations necessary.11,12 To avoid these
diﬃculties, an ideal site-directed conjugation technique would
use residues natural to the protein that are revealed for modiﬁ-
cation only under deﬁned conditions.
Cysteine residues have a low natural abundance in proteins,
and are often found tied up in disulﬁde bonds.13 In the case of
antibodies and antibody fragments there are no free cysteine
residues, and site-directed conjugation has been attempted via
interchain disulﬁde bond reduction and subsequent conjugation
of the free cysteines. However, conjugation of chemical entities
to the generated cysteine residues results in signiﬁcant physical
instability of conjugates, particularly under times of stress.14
Furthermore, targeting the cysteine residues responsible for
interchain disulﬁdes using chemical cross-linking reagents results
in poor yields of bispeciﬁc due to the formation of homodimers
and intrachain coupling.15 Therefore, the ideal solution would be
to use reagents that bridge disulﬁde bonds, maintaining this key
stabilizing feature, and preventing the opportunity for product
heterogeneity.16−23 Herein we propose a conjugation strategy
using simple chemical reagents that selectively bridge disulﬁde
bonds. Through rapid reduction and bridging of disulﬁdes,
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homogeneous bispeciﬁc antibodies could be readily generated
with no eﬀect on stability or activity. To demonstrate the versati-
lity of this chemical conjugation approach to varying antibody
fragment formats, we aimed to generate a homogeneous scFv-
Fab conjugate (Scheme 1).
In prior work we have demonstrated that next generation
maleimides can be used for the extremely eﬃcient rebridging
of disulﬁde bonds in Fab and disulﬁde-stabilized scFv antibody
fragments, to produce fully active, homogeneous protein
conjugates in near-quantitative yields.20,21 Antibody fragments
including Fabs and scFvs are commonly used in a range of
bispeciﬁc topologies. Thus, we envisaged that next generation
maleimide based cross-linking reagents could be used to produce
homogeneous bispeciﬁc constructs. To this end homobifunc-
tional linkers were designed, incorporating two dibromomalei-
mide moieties linked by a PEG chain, conferring some ﬂexibility
to the molecule (Scheme 2). Using commercially available
dibromomaleimide and diamine PEG, two linkers of distinct
length were readily synthesized. The reaction proceeds under mild
conditions in good yield, requiring only a single puriﬁcation step.24
To examine the feasibility of this approach to producing a
homogeneous protein−protein conjugate, we decided to ﬁrst
work with the anti-CEA disulﬁde-stabilized scFv fragment.
Carcinoembryonic antigen (CEA) is a cell surface glycoprotein
overexpressed in a wide range of cancers, particularly in
colorectal carcinoma.25 A scFv is the smallest antibody fragment
which retains full binding activity, and is a common component
of many bispeciﬁc antibody formats, e.g., BiTEs (Bispeciﬁc T-cell
Engager) and DARTs (Dual-Aﬃnity Re-Targetting). Initially,
the ability of the linkers to generate scFv homodimer was
investigated (Scheme 3).
The scFv was reduced (DTT, 20 equiv with respect to
antibody) and, following buﬀer exchange, incubated with 0.5 equiv
of linker BDBM(PEG)2 or BDBM(PEG)19. The conjugation
reaction was monitored by SDS-PAGE, and a distinct band at
∼50 kDa was observed on incubation of BDBM(PEG)19 with
reduced scFv after only 1 h at room temperature (Supporting
Information Figure 1). This corresponds to the molecular weight
of scFv dimer. In contrast, the reduced scFv incubated with linker
BDBM(PEG)2, although rebridged, reveals only a faint band at
∼50 kDa, suggesting poor dimer formation.
The longer length of linker BDBM(PEG)19 (19 PEG units,
∼1 kDa), in combination with its ﬂexibility, is likely to signiﬁ-
cantly reduce steric hindrance which creates diﬃculty when
attempting to link two large proteins. This is observed in the
far greater conversion to homodimer obtained compared to
linker BDBM(PEG)2 (Supporting Information Figure 1). It was
therefore decided that conditions for homogeneous protein−
protein conjugation should be optimized using linker BDBM-
(PEG)19. As a model system, generation of homogeneous scFv
dimer was further pursued in order to determine ideal conditions
for maintaining antibody fragments in their reduced form while
promoting bridging.
Following reduction, the scFv was eluted over a Sephadex
column to remove DTT and to buﬀer exchange the protein
into conditions suitable for maintaining the reduced antibody
(20 mM phosphate buﬀer, 5 mM EDTA, pH 7.4). The antibody
fragment was then concentrated to no greater than 1 mg/mL,
since higher concentrations promoted disulﬁde reoxidation.
A series of optimization experiments revealed incubation with
0.42 equiv of bis-dibromomaleimide cross-linker BDBM(PEG)19
for 1 h at room temperature, or 4 °C overnight, yielded the
highest levels of homogeneous dimer (Supporting Information
Figure 2). In fact, after 1 h approximately 80% of starting material
was consumed (Figure 1[i], lane 3, measured using ImageJ). After
puriﬁcation of the homodimer by size exclusion chromatography,
an excellent 64% yield of pure, homogeneous scFv−scFv
conjugate was obtained from 1 mg of scFv (Figure 1[iii], 75%
yield with respect to the limiting reagent BDBM(PEG)19). This
yield represents a signiﬁcant improvement on previous reports
of direct chemical cross-linking of antibodies using natural amino
acids, which have achieved yields in the 10−40% range.26−29
Notably the conjugate is homogeneous due to the site-selectivity
of the methodology.
Given the success of our technology in generating homo-
geneous scFv homodimer in high yield, we targeted the
generation of a bispeciﬁc antibody conjugate. The monoclonal
Scheme 1. Strategy for the Production of a Homogeneous Bispeciﬁc through Disulﬁde Bridging of Two Antibody Fragments
Scheme 2. Synthetic Route to Linkersa
a(a) ClCO2Me, NMM, THF, 97%; (b) For BDBM(PEG)2: NH2CH2CH2(OCH2CH2)2NH2, DCM, 70%. For BDBM(PEG)19:
NH2CH2CH2(OCH2CH2)19NH2, DCM, 65%.
Scheme 3. Generation of scFv Homodimer
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IgG1 antibody Traztuzumab (Herceptin) targets the HER2/neu
receptor and has successfully been used to treat HER2+ breast
cancer patients.30 The Fab fragment of this clinically relevant
antibody can be readily obtained by enzymatic digest, and its
incorporation into bispeciﬁc formats has therapeutic potential.10
A Fab fragment contains one variable and one constant region of
each of the heavy and light antibody chains, and so is twice the
size of a scFv fragment. The heavy and light chains are covalently
linked via a single interchain disulﬁde bond. Thus, we envisaged
linking the disulﬁde-stabilized scFv to the Fab fragment using
BDBM(PEG)19, generating a conjugate that could simulta-
neously bind two diﬀerent antigens (CEA and HER2) as a proof
of concept (Scheme 4).
To eﬃciently link these two diﬀerent antibody fragments,
we decided to ﬁrst functionalize the scFv with BDBM(PEG)19.
This was cleanly achieved by reducing the scFv as previously
described, purifying by Sephadex column and subsequently
adding 30 equiv of linker to scFv. This reaction was complete in
less than 5 min at room temperature, yielding bromomaleimide
functionalized scFv in quantitative yield (Figure 2[i], lane 3).
Excess linker was removed by buﬀer exchange. In tandem with
this, the Fab fragment was reduced (TCEP, 10 equiv relative to
antibody) and puriﬁed from reducing agent into pH 7.4
phosphate buﬀer containing 5 mM EDTA. The concentrations
of bridged scFv and reduced Fab were adjusted to 37.2 μM
(1 mg/mL for the scFv), and the antibodies mixed in a 2:1 ratio
by volume (2 equiv bridged scFv to 1 equiv reduced Fab).
This slight excess of functionalized scFv was found to be
suﬃcient to promote bridging of the reduced Fab. The reaction
was monitored by SDS-PAGE, and after 1 h at room temperature
a strong band at ∼80 kDa could be observed, corresponding
to the scFv-Fab conjugate. After puriﬁcation by size exclusion
chromatography, a pleasing 52% yield of homogeneous scFv-Fab
bispeciﬁc was achieved.
Next, we used enzyme-linked immunosorbent assay (ELISA)
to assess the immuno-reactivity of the puriﬁed conjugates, in
comparison to the unmodiﬁed scFv and Fab fragments that
bound either CEA or HER2, respectively (Figure 3[i] and [ii]).
Against CEA, the activity of the scFv homodimer was not only
maintained, but remained high at low dilutions, suggesting
dimerization has successfully increased the avidity of the
antibody. Most importantly, the scFv-Fab conjugate showed
comparable antigen binding activity against both CEA and
HER2. Given this success, we wanted to demonstrate that our
heterodimeric conjugate could simultaneously bind its two
target antigens. To achieve this we developed a sandwich ELISA.
A 96-well plate was coated with CEA and the sample to be tested,
e.g., scFv-Fab conjugate, was applied. Subsequent incubation
with HER2-Biotin and Extravadin-Peroxidase would thus only
lead to a signal if the sample successfully bound both CEA and
HER2 antigens. Pleasingly, simultaneous binding activity was
conﬁrmed (Figure 3[iii]). Hence we have successfully produced
a homogeneous antibody conjugate with bispeciﬁc ability using
our disulﬁde-bridging technology.
In a ﬁnal investigation, we assessed the binding of our anti-
body conjugates to a CEA-positive cell line, A375 CEA, and a
HER2-positive cell line, BT-474 (controls shown in Supporting
Information Figure 3). The monomer controls demonstrate
that anti-CEA scFv binds only to A375CEA cells and anti-HER2
Fab only to BT474 cells (Figure 4, monomer). Application of
our scFv homodimer conjugate reveals that CEA binding activity
and selectivity is maintained after conjugation, with a shift in
ﬂuorescence being observed only on the A375CEA cell line
(Figure 4, homodimer). Following this success, we tested our
bispeciﬁc construct (Figure 4, heterodimer). In this case, scFv
and Fab were detected in both the CEA-positive cell line
A375CEA and the HER2-positive BT474. This demonstrates
that the antibody fragments have maintained their distinct
selectivity and binding activity in vitro, while being successfully
chemically linked.
■ CONCLUSION
To date, the generation of bispeciﬁcs for the clinic by chemical
cross-linking has been unsuccessful, due to low yields and
product heterogeneity. Here we have presented the rapid
production of two homogeneous conjugates in high yield: an
Figure 1.Application of optimized conditions to dimerization of scFv: [i] SDS-PAGE analysis (1) scFv; (2) scFv + 20 equiv DTT to aﬀord reduced scFv
(note - scFv with intact disulﬁde runs faster through gel due to more compact structure); (3) reduced scFv + 0.42 equiv BDBM(PEG)19, 1 h rt to aﬀord
scFv homodimer (∼50 kDa) and disulﬁde bridged scFv monomer (∼25 kDa). [ii] Size exclusion chromatography puriﬁcation of pure scFv homodimer
(peak a, ∼50 kDa) from monomer starting materials (peak b) and unreacted linker (peak c) (Superdex 75, GE Healthcare).
Scheme 4. Generation of anti-CEA/anti-HER2 scFv-Fab
Bispeciﬁc
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anti-CEA scFv homodimer and an anti-CEA/anti-HER2 scFv-
Fab heterodimer. Our chemical conjugation approach uses
bis-dibromomaleimide PEG linker readily synthesized over two
steps from the commercially available dibromomaleimide.
Through targeting and bridging the disulﬁde bond of antibody
fragments, conjugates were produced which exhibit retention
of activity by ELISA and cell binding assays. This platform has
the potential to enable the facile generation of bispeciﬁcs from
a range of antibody fragment formats, and could be readily
translated to other protein conjugates of choice, exploiting the
versatility of the chemical conjugation approach.
■ EXPERIMENTAL PROCEDURES
N,N-PEG2-bis-3,4-dibromomaleimide (BDBM(PEG)2).
24
2,2′-(Ethylenedioxy)bis(ethylamine) (0.2 mL, 1.38 mmol)
was added to a stirred solution of N-(methoxycarbonyl)-3,4-
dibromomaleimide24 (1.08 g, 3.45 mmol) in DCM (8 mL).
After 20 min EtOAc (80 mL) was added and the organic layer
Figure 2. Production of homogeneous scFv-Fab: [i] SDS-PAGE analysis (1) scFv; (2) scFv + 20 equiv DTT to aﬀord reduced scFv (note - scFv with
intact disulﬁde runs faster through gel due to more compact structure); (3) Reduced scFv + 30 equiv BDBM(PEG)19 to aﬀord disulﬁde bridged scFv
monomer (note - dibromomaleimide functionalized scFv runs faster than reduced through gel as compact structure is recovered through disulﬁde
bridging); (4) Fab; (5) Fab +10 equiv TCEP to aﬀord component heavy and light Fab chains; (6) Bridged scFv + Reduced Fab (2:1), 1 h rt to aﬀord
scFv-Fab conjugate (∼80 kDa), reoxidized Fab (∼50 kDa) and scFv starting material (∼25 kDa) . [ii] Size exclusion chromatography puriﬁcation of
pure scFv-Fab heterodimer (peak a) from starting materials (peak b and c) (Superdex 75, GE Healthcare).
Figure 3. ELISA analysis of conjugates and unmodiﬁed antibody fragments: [i] ELISA against full length CEA. [ii] ELISA against HER2. [iii] Sandwich
ELISA using full length CEA coated plates and HER2 conjugated to biotin, followed by Extravadin-Peroxidase.
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extracted with saturated NH4Cl solution (2 × 40 mL) and
H2O (3 × 40 mL). The organic layer was dried with MgSO4 and
concentrated in vacuo. Puriﬁcation by column chromatography
(gradient elution from 1:9 to 3:7 EtOAc/Petrol) yielded
BDBM(PEG)2 as a pale yellow solid (600 mg, 70%): mp
116−117 °C; 1H NMR (500 MHz, CDCl3) δ 3.82 (4H, t, J =
5.6 Hz), 3.65 (4H, t, J = 5.6 Hz), 3.58 (4H, s); 13C NMR
(125 MHz, CDCl3) δ 164.2 (C), 129.8 (C), 70.4 (CH2), 68.0
(CH2), 39.3 (CH2); IR (solid) 3489, 2913, 1784, 1720, 1597;
LRMS (ES+) 651 ([81,81,81,81M+Na], 20), 649 ([81,81,81,79M+Na],
70), 647 ([81,81,79,79M+Na], 100), 645 ([81,79,79,79M+Na], 70),
643 ([79,79,79,79M+Na], 20); HRMS (ES+) calculated for
C14H12N2O6Na
79Br4 642.7327, observed 642.7355.
N,N-PEG20-bis-3,4-dibromomaleimide (BDBM(PEG)19).
O,O′-Bis(2-aminoethyl)octadecaethylene glycol (50mg, 0.06mmol)
was added to a stirred solution of N-(methoxycarbonyl)-3,4-
dibromomaleimide24 (44 mg, 0.14 mmol) in DCM (2 mL).
The reaction mixture was left at room temperature overnight,
and then the solvent removed in vacuo. Puriﬁcation by column
chromatography (gradient elution from DCM to 20:1 DCM/
MeOH) yielded BDBM(PEG)19 as a pale yellow oil (53 mg,
65%). 1H NMR (600MHz, CDCl3) δ 3.81 (4H, t, J = 6.0), 3.67−
3.59 (76H, m); 13C NMR (150 MHz, CDCl3) δ 164.0 (C), 129.6
(C), 70.7 (CH2), 70.2 (CH2), 67.7 (CH2), 39.0 (CH2); IR (oil,
cm−1) 2865, 1722; LRMS (EI) 1394 ([81,81,81,81M+NH4], 20),
1392 ([81,81,81,79M+NH4], 70), 1390 ([
81,81,79,79M+NH4], 100),
1388 ([81,79,79,79M+NH4], 70), 1386 ([
79,79,79,79M+NH4], 20),
1346 (40), 1300 (10); HRMS (EI) calculated for
C48H80
81,81,79,79Br4N2O3NH4 1390.2192, observed 1390.2181.
Disulﬁde Bridging of scFv with Linker BDBM(PEG)2 to
Generate scFv−scFv Homodimer. Anti-CEA ds-scFv in PBS
(1 mg/mL, 37.2 μM) was reduced with DTT (20 equiv relative
to scFv, 37.2 mM stock in PBS) for 1 h at room temperature.
DTT was then removed using a desalting column (PD-10,
GE Healthcare) and the reduced scFv buﬀer exchanged into
conjugation buﬀer (20 mM phosphate buﬀer, 5 mM EDTA,
pH 7.4). The scFv was concentrated to approximately 1 mg/mL
and linker BDBM(PEG)2 added (0.42 equiv relative to scFv,
3.72 mM stock in DMF). After 1 h at room temperature or
overnight at 4 °C, the reaction was puriﬁed by size exclusion (500
mL Superdex 75 column, GE Healthcare).
Disulﬁde Bridging of scFv with Linker BDBM(PEG)19 to
Generate scFv−scFv Homodimer. Anti-CEA ds-scFv in PBS
(1 mg/mL, 37.2 μM) was reduced with DTT (20 equiv relative
to scFv, 37.2 mM stock in PBS) for 1 h at room temperature.
DTT was then removed using a desalting column (PD-10, GE
Healthcare) and the reduced scFv buﬀer exchanged into
conjugation buﬀer (20 mM phosphate buﬀer, 5 mM EDTA,
pH 7.4). The scFv was concentrated to approximately 1 mg/mL
and linker BDBM(PEG)19 added (0.42 equiv relative to scFv,
3.72 mM stock in water). After 1 h at room temperature or
overnight at 4 °C, the reaction was puriﬁed by size exclusion
(500 mL Superdex 75 column, GE Healthcare).
Disulﬁde Bridging of scFv and Fab to Generate scFv-
Fab Heterodimer. Anti-CEA ds-scFv in PBS (1 mg/mL,
37.2 μM) was reduced with DTT (20 equiv relative to scFv,
37.2 mM in PBS) for 1 h at room temperature. DTT was then
removed using a desalting column (PD-10, GEHealthcare) and the
reduced scFv buﬀer exchanged into conjugation buﬀer (20 mM
phosphate buﬀer, 5 mM EDTA, pH 7.4). The scFv was con-
centrated to approximately 1 mg/mL and linker BDBM(PEG)19
added (30 equiv relative to scFv, 37.2 mM in water). After 10 min
excess linker was removed by buﬀer exchange (repeat 3 times,
Amicon Ultra-4 Centrifugal Filter Units, 10 kDa cutoﬀ) into
conjugation buﬀer, and the bridged scFv concentrated to
approximately 1 mg/mL. Meanwhile, Herceptin Fab in Borate
buﬀer (1 mg/mL, 25 mM sodium borate, 25 mM NaCl, 1 mM
EDTA, pH 8.0) was reduced with TCEP (10 equiv relative to Fab,
37.2mM in borate buﬀer) for 1 h at room temperature. TCEPwas
then removed using a desalting column (PD-10, GE Healthcare)
and the reduced Fab buﬀer exchanged into conjugation buﬀer
(20 mM phosphate buﬀer, 5 mM EDTA, pH 7.4). The reduced
Fab concentration was adjusted to 37.2 μM, and bridged scFv
(37.2 μM) mixed with the reduced Fab in a 2:1 ratio by volume,
respectively. After 1 h at room temperature or overnight at 4 °C,
the reaction was puriﬁed by size exclusion (500 mL Superdex
75 column, GE Healthcare).
Figure 4. Flow cytometry based binding assay of unmodiﬁed scFv and Fab (monomer), scFv dimer (homodimer), and scFv-Fab conjugate
(heterodimer) to a CEA-positive cell line (A375CEA) and HER2-positive cell line (BT474).
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